Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations, in which other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

Aadi’s initial focus is the treatment of advanced malignant PEComa, an ultra-rare cancer also known as perivascular epithelioid cell tumor. Aadi has also initiated a broader clinical trial of nab-sirolimus for patients with malignant solid tumors harboring inactivating alterations in TSC1 or TSC2 genes.